Trials / Completed
CompletedNCT07020949
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM: A Randomized, Bouble-Blind, Placebo-Controlled Phase Ib Trial
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with T2DM. This study includes three multiple-ascending dose cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | THDBH120 injection | Participants received THDBH120 by subcutaneous injection. |
| DRUG | Placebo of THDBH120 injection | Participants received placebo by subcutaneous injection. |
Timeline
- Start date
- 2024-06-13
- Primary completion
- 2024-11-27
- Completion
- 2024-11-27
- First posted
- 2025-06-13
- Last updated
- 2025-06-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07020949. Inclusion in this directory is not an endorsement.